# Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct06434064/  
OnCo record `nct06434064` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of doxorubicin and tamoxifen in triple-negative breast cancer, run by Roswell Park Cancer Institute, now recruiting.

## Summary

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT06434064 by Roswell Park Cancer Institute, with a registry enrolment figure of 30 participants, started 2026-03-03 and due to reach its primary completion in 2028-11-30. Interventions recorded: Biopsy; Biospecimen Collection; Computed Tomography; Echocardiography; Magnetic Resonance Imaging; Pegylated Liposomal Doxorubicin Hydrochloride; Tamoxifen. Conditions listed: Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Unresectable Triple-Negative Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma. Triple-negative eligibility wording from the registry: "* Patients with pathologically confirmed metastatic triple negative breast cancer (ER ≤ 10%) that have been previously treated with at least 2 lines of therapy in the metastatic setting". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06434064
- Phase: 2
- Setting: A Pilot, Single-Arm, Phase II Trial of Tamoxifen Plus Pegylated Liposomal Doxorubicin in Patients With Metastatic Triple Negative Breast Cancer
- Sponsor: Roswell Park Cancer Institute
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06434064: https://clinicaltrials.gov/study/NCT06434064

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Tamoxifen](https://onco.cc/drugs/tamoxifen/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06434064.json